Lexiva (Fosamprenavir, Telzir)

The Basics | News & Research

Brand Name:	Lexiva
Generic Name:	Fosamprenavir calcium, FPV
Adult Single Dose:	Therapy-naive patients: 1,400 mg twice daily without ritonavir, or 1,400 mg once daily plus ritonavir 200 mg once daily or 700 mg twice daily plus ritonavir 100 mg twice daily. Treatment-experienced patients: 700 mg twice daily plus ritonavir 100 mg twice daily.
Food & Liquid Restrictions:	None
Drug Class:	PI

The Basics

Fosamprenavir (Telzir, Lexiva) (December 19, 2011)
To read PDF, click here.
From AIDS InfoNet
Lexiva (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
An Overview of Lexiva (Fosamprenavir, Telzir) (December 10, 2009)
From AIDSinfo
Lexiva (Fosamprenavir Calcium) -- Dear Health Care Professional Letter (December 3, 2009)
From U.S. Food and Drug Administration
Patient Information About Lexiva (Fosamprenavir, Telzir) (PDF) (September 2009)
From GlaxoSmithKline
Labeling Update for Lexiva (Fosamprenavir) (December 21, 2007)
From U.S. Food and Drug Administration
Lexiva (Fosamprenavir) (November 8, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
Fosamprenavir (908, Lexiva, Telzir) (August 15, 2006)
From AIDS Treatment Data Network
Lexiva (Fosamprenavir) (May 2005)
To read PDF, click here.
From The Center for AIDS
Drug Interactions: Fosamprenavir (August 2004)
From Project Inform
Fosamprenavir: A New Protease Inhibitor Option (February 2004)
An interview with Jeffrey Nadler, principal investigator of the pivotal NEAT study.
To read PDF, click here.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Waiting in the Wings: More New Drugs (November/December 2003)
[Archived Article]
A look at 908, TMC-125 and entry inhibitors in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
FDA Approves Lexiva (Fosamprenavir Calcium) (October 21, 2003)
[Archived Article]
From U.S. Food and Drug Administration
Position Paper on 908 (Fosamprenavir, Lexiva) (October 13, 2003)
[Archived Article]
To read PDF, click here.
In TAGline, from Treatment Action Group

News & Research

Clinical Trials Using Fosamprenavir (Lexiva) (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Literature Citations for Fosamprenavir (Lexiva) (Regularly Updated)
From U.S. National Institutes of Health
Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
To read PDF, click here.
FDA: HIV Drug Lexiva Label to Warn of Cholesterol Increases (December 4, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here.
From GlaxoSmithKline
FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration
Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Fosamprenavir + Ritonavir Appears Safe Through 120 Weeks in HIV/HBV and HIV/HCV-Coinfected Patients (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Lexiva: Blood Levels Not Lowered When Taken Simultaneously With Esomeprazole (Nexium) (June 20, 2005)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
Don't Combine Fosamprenavir and Lopinavir/Ritonavir (February/March 2005)
[Archived Article]
From The Body PRO
Boosted Fosamprenavir Works Well as First-Line Therapy (July 23, 2004)
[Archived Article]
A HAART regimen containing fosamprenavir and ritonavir is highly effective and well-tolerated when used as first-line therapy in patients with advanced HIV, according to the final published results from this major study.
In AIDS
Fosamprenavir Update (July 13, 2004)
[Archived Article]
Recaps of studies on treatment-naive patients, switching from amprenavir and fosamprenavir resistance.
In The XV International AIDS Conference, from The Body PRO
Lexiva + Kaletra -- Still a Bad Idea (March/April 2004)
[Archived Article]
A short review of a study presented at CROI 2004.
In Positively Aware, from Test Positive Aware Network
The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy-Naive HIV-1-Infected Patients (January 2004)
[Archived Article]
In Journal of Acquired Immune Deficiency Syndrome
Summary of Fosamprenavir Studies on Treatment-Naive and Protease Inhibitor-Experienced Patients (November 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
The FDA Has Just Approved Lexiva, a New Anti-HIV Medication (October 27, 2003)
[Archived Article]
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
Pharmacokinetic Interactions of 908 (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
908 Plus Lopinavir/Ritonavir Does Not Appear to Be a Viable Regimen for HIV-Infected Patients (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
908 vs. Kaletra: Comparable for Experienced Patients, Not for Naive (July 28, 2003)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Lower Rate of Resistance Seen in Boosted 908 Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Fosamprenavir: First Line or Later? (April 2003)
[Archived Article]
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
The NEAT Study: GW433908 Efficacy and Safety in ART-Naive Subjects: Final 48-Week Analysis (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Context Study: Efficacy and Safety of GW433908/RTV in PI-Experienced Subjects With Virological Failure (24 Week Results) (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Effect of Amprenavir Hypersusceptibility on the Response to APV/Ritonavir-Based Therapy in ART-Experienced Adults Selected by Baseline Susceptibility (ESS40006): 24-Week Data (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
GW433908 in ART-Naive Subjects: Absence of Resistance at 48 Weeks With Boosted Regimen and APV-Like Resistance Profile With Unboosted Regimen (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
New Drug Holds Promise of Once-Daily Therapy (December 20, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy-Naive Subjects, 48-Week Results -- The SOLO Study (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
GW433908, a Novel Prodrug of the HIV Protease Inhibitor (PI) Amprenavir (APV): Safety, Efficacy, and Pharmacokinetics (PK) (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO

My Health Tracker

Assess Your Risk for HIV

U.S. ASO Finder

Find a Therapist

What Really Fuels the HIV/AIDS Epidemic in Black America?

Top 10 HIV/AIDS-Related Clinical Developments of 2011

Ten HIV/AIDS Stories that Defined 2011

The Culture War in the Black HIV/AIDS Movement Is Hurting Us All

Tennessee Senator: It's Virtually Impossible for Heterosexuals to Contract HIV From Sex: A Blog Entry by Kellee Terrell

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.